Exploring Factor XI: A Paradigm Shift as a Hemostasis Sparing Anticoagulant

1:45 PM - 2:45 PM (PDT), Tuesday, June 14, 2022 ・ Upper Level, Session Room 1B

Hemostasis and thrombosis are believed to be so intricately linked that any strategies that reduce thrombosis will have an inevitable impact on hemostasis. Consequently, bleeding is viewed as an unavoidable side effect of anticoagulant therapy. Emerging evidence suggests that Factor XI is important for thrombosis but has a minor role in hemostasis. This raises the possibility that anticoagulants that target Factor XI will be safer than currently available agents1. This panel will explore the promise of Factor XI inhibition and how it may address many important unmet patient needs.1 JACC, Vol. 78,No.6, 2021

Moderator
photo
Chief Executive Officer
Anthos Therapeutics
Speakers
photo
Professor of Pathology and Medicine
Vanderbilt University
photo
CEO
StopAfib.org
photo
President
Thrombosis Research Institute in London
photo
Associate Professor of Hemotology
Tel Aviv University